An Update on Antimicrobial Peptides (AMPs) and Their Delivery Strategies for Wound Infections
Open Access
- 2 September 2020
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (9) , 840
Abstract
Bacterial infections occur when wound healing fails to reach the final stage of healing, which is usually hindered by the presence of different pathogens. Different topical antimicrobial agents are used to inhibit bacterial growth due to antibiotic failure in reaching the infected site, which is accompanied very often by increased drug resistance and other side effects. In this review, we focus on antimicrobial peptides (AMPs), especially those with a high potential of efficacy against multidrug-resistant and biofilm-forming bacteria and fungi present in wound infections. Currently, different AMPs undergo preclinical and clinical phase to combat infection-related diseases. AMP dendrimers (AMPDs) have been mentioned as potent microbial agents. Various AMP delivery strategies that are used to combat infection and modulate the healing rate—such as polymers, scaffolds, films and wound dressings, and organic and inorganic nanoparticles—have been discussed as well. New technologies such as Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated protein (CRISPR-Cas) are taken into consideration as potential future tools for AMP delivery in skin therapy.Keywords
All Related Versions
This publication has 209 references indexed in Scilit:
- The antibiotic planosporicin coordinates its own production in the actinomycete Planomonospora albaProceedings of the National Academy of Sciences, 2013
- Preparation and characterization of flexible nanoliposomes loaded with daptomycin, a novel antibiotic, for topical skin therapyInternational Journal of Nanomedicine, 2013
- In Vitro Activities of LTX-109, a Synthetic Antimicrobial Peptide, against Methicillin-Resistant, Vancomycin-Intermediate, Vancomycin-Resistant, Daptomycin-Nonsusceptible, and Linezolid-Nonsusceptible Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2012
- Role of host-defence peptides in eye diseasesCellular and Molecular Life Sciences, 2011
- Activity of Telavancin against Staphylococci and Enterococci Determined by MIC and Resistance Selection StudiesAntimicrobial Agents and Chemotherapy, 2009
- Human Host Defense Peptide LL-37 Prevents Bacterial Biofilm FormationInfection and Immunity, 2008
- Correlation of MIC with Outcome for Candida Species Tested against Caspofungin, Anidulafungin, and Micafungin: Analysis and Proposal for Interpretive MIC BreakpointsJournal of Clinical Microbiology, 2008
- Efficacy of Tachyplesin III, Colistin, and Imipenem against a Multiresistant Pseudomonas aeruginosa StrainAntimicrobial Agents and Chemotherapy, 2007
- Dalbavancin: a novel antimicrobialInternational Journal Of Clinical Practice, 2007
- Safety Study of an Antimicrobial Peptide Lactocin 160, Produced by the VaginalLactobacillus rhamnosusInfectious Diseases in Obstetrics and Gynecology, 2007